GlycoMimetics, Inc.
08/03/2017
PDF
Add to Briefcase

GlycoMimetics Reports Program Updates and Second Quarter 2017 Results

FDA granted Breakthrough Therapy designation to the Company's drug candidate, GMI-1271, for treatment of adults with relapsed/refractory acute myeloid leukemia (AML)
  • Company completed enrollment in the in Phase 2 portion of its Phase 1/2 trial of GMI-1271 for the treatment of AML
  • Clinicians presented interim clinical data from the Phase 1/2 trial of GMI-1271 for the treatment of AML at the 2017 American Society of Clinical Oncology (ASCO) and European Hematology Association (EHA) meetings
  • Company completed public offering raising gross proceeds of $92.6 million
  • ROCKVILLE, Md.--(BUSINESS WIRE)-- GlycoMimetics, Inc. (NASDAQ: GLYC) today reported progress on its clinical development programs and its financial results for the second quarter and six months ended June 30, 2017.

    "In the second quarter of 2017, GlycoMimetics achieved multiple milestones for its GMI-1271 program, a highlight of which was the FDA's granting of Breakthrough Therapy designation to GMI-1271 for the treatment of relapsed/refractory AML patients. This milestone was coupled with the presentation of updated data from our ongoing Phase 1/2 clinical trial at both the ASCO and EHA meetings and the completion of a public offering of our common stock, from which we raised gross proceeds of $92.6 million to significantly extend our cash runway. We believe that these milestones provide evidence of the opportunity residing in our GMI-1271 program and our drug development platform more generally. The achievements during the second quarter have importantly underscored the differentiated potential of GMI-1271," noted Rachel King, Chief Executive Officer.

    "The recent spotlight on our fast-progressing program in AML, however, should not obscure the potential of our platform and broad pipeline opportunities. In particular, GMI-1359, is a compound with potential in multiple cancer indications and is now in Phase 1 trials in healthy volunteers. During 2018, we plan to identify the initial patient population in which we will evaluate this compound. In addition, our most advanced clinical development program to evaluate GlycoMimetics' drug candidate rivipansel for the treatment of vaso-occlusive crisis of sickle cell diseases, is on track to complete enrollment of the Phase 3 pivotal trial in the second half of 2018, according to our collaborator Pfizer," she added.

    Key Operational Highlights for the Second Quarter of 2017:

    Second Quarter 2017 Financial Results:

    About GMI-1271

    GMI-1271 is designed to block E-selectin (an adhesion molecule on cells in the bone marrow) from binding with blood cancer cells as a targeted approach to disrupting well-established mechanisms of leukemic cell resistance within the bone marrow microenvironment. In a Phase 2 clinical trial which has now completed enrollment, GMI-1271 is being evaluated in both elderly and relapsed/refractory patients with acute myeloid leukemia (AML). In both populations, patients treated with GMI-1271 together with standard chemotherapy have continued to achieve higher than expected remission rates based on historical controls, as well as lower than expected induction-related mortality rates. Importantly, treatment in this patient population has been well tolerated with minimal adverse effects.

    About GMI-1359

    GMI-1359 is designed to simultaneously inhibit both E-selectin and CXCR4. E-selectin and CXCR4 are both adhesion molecules that keep cancer cells in the bone marrow. Preclinical studies indicate that targeting both E-selectin and CXCR4 with a single compound could improve efficacy in the treatment of cancers that involve the bone marrow such as AML and MM or in solid tumors that metastasize to the bone, such as prostate cancer and breast cancer. GMI-1359 is currently in Phase 1 testing in healthy volunteers.

    About GlycoMimetics, Inc.

    GlycoMimetics is a clinical-stage biotechnology company focused on the discovery and development of novel glycomimetic drugs to address unmet medical needs resulting from diseases in which carbohydrate biology plays a key role. GlycoMimetics' most advanced drug candidate, rivipansel, a pan-selectin antagonist, is being developed for the treatment of vaso-occlusive crisis in sickle cell disease and is being evaluated in a Phase 3 clinical trial being conducted by its strategic collaborator, Pfizer. GlycoMimetics' wholly-owned drug candidate, GMI-1271, an E-selectin antagonist, is being evaluated in an ongoing Phase 2 clinical trial as a potential treatment for AML and in a Phase 1 clinical trial for the treatment of multiple myeloma. The FDA recently granted GMI-1271 Breakthrough Therapy designation for the treatment of adult AML patients with relapsed/refractory disease. GlycoMimetics has also recently initiated a Phase 1 clinical trial with a third drug candidate, GMI-1359, a combined CXCR4 and E-selectin antagonist. GlycoMimetics is located in Rockville, MD in the BioHealth Capital Region. Learn more at www.glycomimetics.com.

    Cautionary Note Regarding Forward-Looking Statements

    This press release contains forward-looking statements regarding the clinical development of the company's drug candidates, including the expected timing of completion of clinical trials and the presentation of clinical data. Actual results may differ materially from those in these forward-looking statements. For a further description of the risks associated with these statements, as well as other risks facing GlycoMimetics, please see the risk factors described in the company's annual report on Form 10-K that was filed with the U.S. Securities and Exchange Commission (SEC) on March 1, 2017, and other filings GlycoMimetics makes with the SEC from time to time. Forward-looking statements speak only as of the date of this release, and GlycoMimetics undertakes no obligation to update or revise these statements, except as may be required by law.

     
    GlycoMimetics, Inc.
    Condensed Statements of Operations
    (In thousands, except share and per share data)
         
    Three months ended June 30,   Six months ended June 30,
    (Unaudited) (Unaudited)
    2017 2016 2017 2016
     
    Revenue $ - $ - $ - $ -
     
    Cost and expenses:
    Research and development expense 5,722 5,781 11,601 11,300
    General and administrative expense   2,522     2,312     4,614     4,369  
    Total costs and expenses   8,244     8,093     16,215     15,669  
     
    Loss from operations (8,244 ) (8,093 ) (16,215 ) (15,669 )
     
    Other income   102     22     142     42  
     
    Net loss and comprehensive loss $ (8,142 ) $ (8,071 ) $ (16,073 ) $ (15,627 )
     
     
     
    Net loss per share - basic and diluted $ (0.30 ) $ (0.41 ) $ (0.63 ) $ (0.80 )
    Weighted average shares - basic and diluted 27,239,902 19,793,202 25,360,167 19,432,520
     
     
    GlycoMimetics, Inc.
    Balance Sheet Data
    (In thousands)
       
    June 30, December 31,
    2017 2016
    (unaudited)
     
    Cash and cash equivalents $ 119,148 $ 40,042
     
    Working capital 114,203 34,187
     
    Total assets 121,622 42,388
     
    Total liabilities 6,190 7,087
     
    Stockholders' equity 115,432 35,301
     

    GlycoMimetics, Inc.
    Investor Contact:
    Shari Annes, 650-888-0902
    sannes@annesassociates.com
    or
    Media Contact:
    Jamie Lacey-Moreira, 410-299-3310
    jamielacey@presscommpr.com

    Source: GlycoMimetics, Inc.

    News Provided by Acquire Media